Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.

CPE-002 · synthetic case CPE002-EX-02

Patient on insulin therapy with a high insulin level

Insulin 30 µIU/mL in a patient who injects insulin, with fasting glucose 150 mg/dL.

Synthetic · no real patientExtended demonstration caseMetabolic engine v1.0.0

Purpose: Insulin 30 µIU/mL in a patient who injects insulin, with fasting glucose 150 mg/dL.

Inputs the engine received

Patient

Age
62 years

Context

Sex for threshold application
male
Active medication list available
Yes
Fasting confirmed
Yes
Insulin therapy active
Yes
Glucose lowering medication active
Yes

Laboratory

Fasting plasma glucose
150 mg/dL
Fasting insulin
30 µIU/mL

What the engine reports

Priority

Diabetes-range laboratory finding

SAFE-GLY-001

A guideline diabetes-range criterion is met. Physician review and confirmation per standards of care are required.

Detected clinical pattern

Diabetes-Range Finding — Physician Review

At least one guideline diabetes-range criterion is met; physician review and confirmation are required.

  • Glycemic: Diabetes-Range Finding — Physician Review
  • Validity: Interpretation limited
  • Metabolic syndrome: Metabolic syndrome: incomplete assessment
  • IR-associated pattern: IR-associated pattern: not assessable
  • Safety: Priority review

Why this pattern was identified

  • Glycemic criteria met. FPG in diabetes range.

Recommended next steps

For physician consideration. Urgent review always comes first.

  1. 1Confirm the diabetes-range finding per standards of care and review diabetes type.Diabetes-range criterion met.
  2. 2Interpret with the listed validity modifiers in mind.treated metabolic state present; insulin measurement not interpretable for baseline pattern

Differentials, pitfalls and contradicting signals

  • Diabetes type (type 2, type 1/LADA, monogenic, secondary) is a physician determination.
  • Treated metabolic state: glucose, insulin and lipid values may be modified by therapy.

Missing information

  • Metabolic syndrome components not entered: Elevated waist circumference; Triglycerides ≥150 mg/dL (or treated); Low HDL-C (men <40, women <50 mg/dL); BP ≥130/85 mmHg (or treated).
Evidence and rule trace · 9 rules

VALIDITY-003Treated Metabolic State

Inputs: glucose-lowering medication

TREATED_METABOLIC_STATE_PRESENT

VALIDITY-004Exogenous Insulin or Secretagogue Suppression

Inputs: insulin therapy

INSULIN_MEASUREMENT_NOT_INTERPRETABLE_FOR_BASELINE_PATTERN

SAFE-GLY-001Diabetes-Range Laboratory Finding

Inputs: FPG 150 mg/dL

DIABETES_RANGE_FINDING_REQUIRES_PHYSICIAN_REVIEW

METS-COMP-005Fasting glucose ≥100 mg/dL (or treated)

Inputs: on glucose-lowering medication

METS_GLUCOSE_COMPONENT_MET

MISS-002Metabolic Syndrome Incomplete Data

Inputs: 1 of 5 components met · missing: Elevated waist circumference; Triglycerides ≥150 mg/dL (or treated); Low HDL-C (men <40, women <50 mg/dL); BP ≥130/85 mmHg (or treated)

METABOLIC_SYNDROME_ASSESSMENT_INCOMPLETE

IRP-002Hyperinsulinemic Supporting Patternsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

IRP-003Elevated HOMA-IR Supporting Findingsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

IRP-004Convergent IR-Associated Patternsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

TREND-MET-001Composite Metabolic Deterioration Warningsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

FASTING_INSULIN_PATTERN_CLASSIFICATIONfasting insulin pattern classificationsuppressed

Suppressed by a validity or safety rule.

HOMA_IR_PATTERN_CLASSIFICATIONhoma ir pattern classificationsuppressed

Suppressed by a validity or safety rule.

Evidence

  • EV-ADA-2026-DIAG · American Diabetes Association Professional Practice Committee for Diabetes. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
  • EV-METS-2009 · IDF/AHA/NHLBI/WHF/IAS/IASO Joint Interim Statement. Harmonizing the Metabolic Syndrome. Circulation. 2009;120:1640-1645.

Physician adjudication required. Clinical decision support only. This output identifies guideline-based glycemic and metabolic findings and risk context. It does not diagnose insulin resistance, select treatment or recommend medication. Physician adjudication is required.

Change the values

The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.

Glycemic testsDrag the sliders to cross a threshold
  • <100
  • 100–125 prediabetes
  • ≥126 diabetes range
  • <5.7
  • 5.7–6.4 prediabetes
  • ≥6.5 diabetes range

75-g protocol

Lipids, body and blood pressure
  • <150
  • 150–499
  • ≥500 priority
  • ≥1000 urgent

Metabolic syndrome components1 of 5

  • ○ Waist not entered
  • ○ Triglycerides not entered
  • ○ Low HDL-C not entered
  • ○ Blood pressure not entered
  • ● Fasting glucose met

● met · ◌ not met · ○ not entered. Three or more meet the criteria; that does not confirm insulin resistance.

Patient and scope
Sex for thresholds
Ketones
Symptoms and safety
Risk context
Liver context
Medications
Outside the standard adult runtime
Fasting insulin (supporting only)Calculation and sandbox

Shown with HOMA-IR when fasting and same-collection are confirmed. It does not classify anything.

Research sandbox (unvalidated)

In production the insulin and HOMA-IR rules are off: no validated threshold profile exists. Here you can supply your own threshold to see how the sandbox rules would behave. The output is labeled a sandbox candidate and is never a diagnosis.

Live result · computed in your browser

Priority

Diabetes-range laboratory finding

SAFE-GLY-001

A guideline diabetes-range criterion is met. Physician review and confirmation per standards of care are required.

Detected clinical pattern

Diabetes-Range Finding — Physician Review

At least one guideline diabetes-range criterion is met; physician review and confirmation are required.

  • Glycemic: Diabetes-Range Finding — Physician Review
  • Validity: Interpretation limited
  • Metabolic syndrome: Metabolic syndrome: incomplete assessment
  • IR-associated pattern: IR-associated pattern: not assessable
  • Safety: Priority review

Why this pattern was identified

  • Glycemic criteria met. FPG in diabetes range.

Recommended next steps

For physician consideration. Urgent review always comes first.

  1. 1Confirm the diabetes-range finding per standards of care and review diabetes type.Diabetes-range criterion met.
  2. 2Interpret with the listed validity modifiers in mind.treated metabolic state present; insulin measurement not interpretable for baseline pattern

Differentials, pitfalls and contradicting signals

  • Diabetes type (type 2, type 1/LADA, monogenic, secondary) is a physician determination.
  • Treated metabolic state: glucose, insulin and lipid values may be modified by therapy.

Missing information

  • Metabolic syndrome components not entered: Elevated waist circumference; Triglycerides ≥150 mg/dL (or treated); Low HDL-C (men <40, women <50 mg/dL); BP ≥130/85 mmHg (or treated).
Evidence and rule trace · 9 rules

VALIDITY-003Treated Metabolic State

Inputs: glucose-lowering medication

TREATED_METABOLIC_STATE_PRESENT

VALIDITY-004Exogenous Insulin or Secretagogue Suppression

Inputs: insulin therapy

INSULIN_MEASUREMENT_NOT_INTERPRETABLE_FOR_BASELINE_PATTERN

SAFE-GLY-001Diabetes-Range Laboratory Finding

Inputs: FPG 150 mg/dL

DIABETES_RANGE_FINDING_REQUIRES_PHYSICIAN_REVIEW

METS-COMP-005Fasting glucose ≥100 mg/dL (or treated)

Inputs: on glucose-lowering medication

METS_GLUCOSE_COMPONENT_MET

MISS-002Metabolic Syndrome Incomplete Data

Inputs: 1 of 5 components met · missing: Elevated waist circumference; Triglycerides ≥150 mg/dL (or treated); Low HDL-C (men <40, women <50 mg/dL); BP ≥130/85 mmHg (or treated)

METABOLIC_SYNDROME_ASSESSMENT_INCOMPLETE

IRP-002Hyperinsulinemic Supporting Patternsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

IRP-003Elevated HOMA-IR Supporting Findingsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

IRP-004Convergent IR-Associated Patternsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

TREND-MET-001Composite Metabolic Deterioration Warningsandbox · off

Sandbox rule — disabled by default. Needs an assay-specific threshold profile and external endocrinology validation.

FASTING_INSULIN_PATTERN_CLASSIFICATIONfasting insulin pattern classificationsuppressed

Suppressed by a validity or safety rule.

HOMA_IR_PATTERN_CLASSIFICATIONhoma ir pattern classificationsuppressed

Suppressed by a validity or safety rule.

Evidence

  • EV-ADA-2026-DIAG · American Diabetes Association Professional Practice Committee for Diabetes. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
  • EV-METS-2009 · IDF/AHA/NHLBI/WHF/IAS/IASO Joint Interim Statement. Harmonizing the Metabolic Syndrome. Circulation. 2009;120:1640-1645.

Physician adjudication required. Clinical decision support only. This output identifies guideline-based glycemic and metabolic findings and risk context. It does not diagnose insulin resistance, select treatment or recommend medication. Physician adjudication is required.

More metabolic cases

All metabolic cases

The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.

Contact Biod